Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.45 |
| ▸ | STK17B | O94768 | 1/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20510973 | 0.90 | STK17B (0.49) | MEN1KMT2AMAPTMAPK1NFKB1 | |
| SCHEMBL18538932 | 0.83 | KCNH3 (0.68) | MEN1KMT2ALMNANPC1RAB9A | |
| SCHEMBL12377130 | 0.81 | NPC1 (0.62) | MEN1KMT2AMAPTMAPK1NFKB1 | |
| SCHEMBL1923883 | 0.79 | MAPT (1.00) | MEN1KMT2AMAPTMAPK1NFKB1 | |
| SCHEMBL8386481 | 0.78 | NPC1 (0.57) | MEN1KMT2AMAPTMAPK1NFKB1 | |
| SCHEMBL11810922 | 0.77 | MAPT (0.73) | MEN1KMT2AMAPTMAPK1NFKB1 | |
| SCHEMBL3499751 | 0.76 | MAPT (0.85) | MEN1KMT2AMAPTMAPK1NFKB1 | |
| SCHEMBL23643402 | 0.76 | NFKB1 (0.92) | MEN1KMT2AMAPTMAPK1NFKB1 | |
| SCHEMBL113103 | 0.76 | NFKB1 (1.00) | MEN1KMT2AMAPTMAPK1NFKB1 | |
| SCHEMBL21655135 | 0.76 | NFKB1 (1.00) | MEN1KMT2AMAPTMAPK1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | claimed |
| US-7608620-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-10-27 | — | — | US | claimed |
| US-20070072856-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-03-29 | — | — | US | claimed |
| US-7064125-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2006-06-20 | — | — | US | claimed |
| US-20060035896-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| US-20040162288-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-08-19 | — | — | US | claimed |
| WO-2002036578-A9 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2004-04-22 | — | — | WO | claimed |
| US-20030100557-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2003-05-29 | — | — | US | claimed |
| US-20020103195-A1 | LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS,INC. | 2002-08-01 | — | — | US | claimed |
| WO-2002036578-A2 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | claimed |
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7608620-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608620-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20040162288-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-08-19 | — | — | US | disclosed |
| WO-2002036578-A9 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20030100557-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020103195-A1 | LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS,INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002036578-A2 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035896-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MEN1 2047/4885KMT2A 120/4885MAPT 2134/4885 |
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | LPCAT3, LPCAT1, PLAAT2 | MEN1 2590/4885KMT2A 326/4885MAPT 2807/4885 |
| US-20020103195-A1 | LPAAT-B inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MEN1 2591/4885KMT2A 158/4885MAPT 3108/4885 |
| US-20070072856-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MEN1 2590/4885KMT2A 326/4885MAPT 2807/4885 |
| US-20040162288-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MEN1 2484/4885KMT2A 312/4885MAPT 2914/4885 |
| US-20030100557-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MEN1 2484/4885KMT2A 312/4885MAPT 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.